Complete Response to Sequential Human Epidermal Growth Factor Receptor 2-Targeted Strategies in a Heavily Pretreated Patient With Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Bladder Cancer

Nenhuma Miniatura disponível
Citações na Scopus
Tipo de produção
article
Data de publicação
2023
DOI
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
JR, Nildevande F. Lima
SAMPAIO, Luana A. F.
XAVIER, Camila B.
MATTEDI, Romulo L.
QUEIROZ, Marcelo A.
JARDIM, Denis L.
Citação
JCO PRECISION ONCOLOGY, v.7, article ID e2200414, 7p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/57810
Referências
  1. [Anonymous], A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors (KAMELEON)
  2. Behzatoglu K, 2018, EUR UROL FOCUS, V4, P399, DOI 10.1016/j.euf.2016.06.007
  3. Bogen JP, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.672262
  4. Choudhury NJ, 2016, J CLIN ONCOL, V34, P2165, DOI 10.1200/JCO.2015.66.3047
  5. Costa LB, 2021, RADIOGRAPHICS, V41, P120, DOI 10.1148/rg.2021200093
  6. Eaton JS, 2015, J OCUL PHARMACOL TH, V31, P589, DOI 10.1089/jop.2015.0064
  7. Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, P1, DOI 10.1007/978-1-4419-0685-4_1
  8. Ferraro E, 2021, BREAST CANCER RES, V23, DOI 10.1186/s13058-021-01459-y
  9. Galsky MD, 2012, INVEST NEW DRUG, V30, P695, DOI 10.1007/s10637-010-9541-0
  10. Galsky MD., 2022, J Clin Oncol, V40
  11. Hu-Lieskovan S, 2021, FUTURE ONCOL, V17, P1401, DOI 10.2217/fon-2020-0967
  12. Hussain MHA, 2007, J CLIN ONCOL, V25, P2218, DOI 10.1200/JCO.2006.08.0994
  13. Ikeda S, 2022, J CLIN ONCOL, V40
  14. Krüger S, 2002, INT J ONCOL, V21, P981
  15. Laé M, 2010, ANN ONCOL, V21, P815, DOI 10.1093/annonc/mdp488
  16. Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105
  17. Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
  18. Meric-Bernstam F., 2021, J Clin Oncol, V39
  19. Meric-Bernstam F, 2022, J CLIN ONCOL, V40
  20. Mitani S, 2020, CANCERS, V12, DOI 10.3390/cancers12020400
  21. Modi S, 2020, NEW ENGL J MED, V382, P610, DOI 10.1056/NEJMoa1914510
  22. Müller P, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4925
  23. Nishino M, 2018, CANCER IMMUNOL RES, V6, P630, DOI 10.1158/2326-6066.CIR-17-0715
  24. Oudard S, 2015, EUR J CANCER, V51, P45, DOI 10.1016/j.ejca.2014.10.009
  25. Patelli G, 2022, CANCER TREAT REV, V104, DOI 10.1016/j.ctrv.2022.102351
  26. Peng M, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.539527
  27. Pondé N, 2020, EUR J CANCER, V126, P65, DOI 10.1016/j.ejca.2019.11.023
  28. Powles T, 2017, J CLIN ONCOL, V35, P48, DOI 10.1200/JCO.2015.66.3468
  29. Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007
  30. Ruiz-Saenz A, 2018, CANCER RES, V78, P3645, DOI 10.1158/0008-5472.CAN-18-0430
  31. Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7
  32. Sheng X, 2022, J CLIN ONCOL, V40
  33. Sheng XA, 2021, CLIN CANCER RES, V27, P43, DOI 10.1158/1078-0432.CCR-20-2488
  34. Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
  35. Waks AG, 2020, J CLIN ONCOL, V38
  36. Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
  37. Wülfing C, 2009, CANCER-AM CANCER SOC, V115, P2881, DOI 10.1002/cncr.24337
  38. Xu HY, 2022, J CLIN ONCOL, V40
  39. Yan M, 2015, CANCER METAST REV, V34, P157, DOI 10.1007/s10555-015-9552-6
  40. ZHAU HE, 1990, MOL CARCINOGEN, V3, P254, DOI 10.1002/mc.2940030503
  41. Zhou L., 2022, J Clin Oncol, V40

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55